Table 1

Baseline characteristics of the included studies

TrialYearNMean Follow-up (months)Mean age (years)Per cent maleMean EF (%)Per cent IHDPer cent DM
1Calkins et al23SCV vs cephalic approach20017118656142NANA
2Deisenhofer et al24Dual vs single chamber20019286190NA67NA
3Kron et al8AVID2001539276579328126
4Bänsch et al25CAT200250665286240NA
5Moss et al26MADIT20027422064842310033
6Vollman et al276944 vs 694220035421165833472NA
7Bänsch et al281+1200410212NANA3882NA
8Bokhari et al29CIDS subset200460676483348012
9Hohnloser et al30DINAMIT20043103062812810031
10Kadish et al11DEFINITE200422929587221023
11Bänsch et al31Quick-ICD20071901263864164NA
12Reddy et al32SMASH-VT20071282267873210044
13Almendral et al10DATAS2008334156484368524
14Russo et al33INTRINSIC RV20091530116581NA5827
15Steinbeck et al7IRIS2009415376383357737
16Kuck et al34VTACH201010723669334100NA
17Varma et al35TRUST201013391164722967NA
18Cheng et al36Warfarin20111617179374923
Summary estimate679617.9648030.574.029.1
  • DM, diabetes mellitus; IHD, ischaemic heart disease; NA, not available.